Skip to main content

A Phase 1 Study in Patients With HPV+ Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma

Trial Status: Active

This is a multi center, open-label, phase 1 dose escalation and expansion study evaluating the safety, anti-tumor effect, and immunogenicity of CUE-101 as monotherapy treatment in second line or CUE-101 Combination Therapy with Pembrolizumab in first line patients with HPV+ Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Inclusion Criteria

  • Ability to provide informed consent and documentation of informed consent prior to initiation of any study-related tests or procedures that are not part of standard of care for the patient's disease. Patients must also be willing and able to comply with study procedures, including the acquisition of specified research specimens.
  • Age ≥ 18 years old
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Life expectancy ≥ 12 weeks
  • Measurable disease as per RECIST 1.1 and documented by computed tomography (CT) and/or magnetic resonance imaging (MRI). Cutaneous or subcutaneous lesions must be measurable by calipers. Note: Lesions to be used as measurable disease for the purpose of response assessment must either a) not reside in a field that has been subjected to prior radiotherapy, or b) have demonstrated clear evidence of radiographic progression since the completion of prior radiotherapy and prior to study enrollment.
  • Recurrent and metastatic HNSCC that has progressed following at least 1 prior systemic therapy. Patients must have received platinum-based chemotherapy and/or pembrolizumab in the first-line setting
  • Patient must have HLA-A*0201 genotype as determined by genomic testing performed at a central laboratory determined by the Sponsor prior to enrollment.
  • Patient must have histologically and/or cytologically proven tumor(s) that are HPV16 positive and express 16INK4A. Archival tissue or formalin-fixed, paraffin-embedded (FFPE) tissue from a biopsy and / or surgery must be available for HPV16 and p16INK4A testing on all patients enrolled. All tumors must test positive for HPV16 using ISH analysis and p16INK4A expression in tumor cells using IHC analysis performed at a central laboratory determined by the Sponsor prior to enrollment.
  • All tumors must have histologically or cytologically confirmed diagnoses. Laboratory Features
  • Acceptable laboratory parameters as follows:
  • Platelet count ≥ 100 x 103/µL
  • Hemoglobin ≥ 9.0 g/dL
  • Absolute neutrophil count ≥ 1.5 × 103/µL in the absence of any growth factor support within 2 weeks prior to the initiation of study drug
  • ALT or AST ≤ 3.0 × upper limit of normal (ULN); for patients with hepatic metastases, ALT and AST ≤ 5 × ULN
  • Total bilirubin ≤ 1.5 × ULN, except patients with Gilbert's syndrome, who may enroll if the conjugated bilirubin (total and direct) is within normal limits
  • Creatinine < 1.5 mg/dL, or a calculated or measured creatinine clearance > 30 mL/min. Reproductive Features
  • Female patients of childbearing potential (not surgically sterilized and between menarche and 1 year post-menopause) must have a negative serum pregnancy test performed within 72 hours prior to the initiation of study drug administration. Further, female patients of childbearing potential must agree to use acceptable contraceptive measures from the time of consent through 30 days after discontinuation of study drug administration. For female patients, 2 forms of contraception must be utilized and may include oral, transdermal, injectable or implantable contraceptives, intrauterine device, female condom, diaphragm with spermicide, cervical cap, use of a condom by the sexual partner or a sterile or vasectomized sexual partner. Periodic abstinence (eg, calendar, ovulation, symptothermal, and post ovulation methods) and withdrawal are not considered acceptable forms of contraception in this study.
  • Non-vasectomized male patients with partners of childbearing potential must use barrier contraception. In addition, male patients should also have their partners use another method of contraception from the time of consent through 30 days after discontinuation of study drug administration
  • Female patients should not be pregnant or plan to become pregnant during the course of the trial.
  • Female patients must not be breastfeeding. Previous Checkpoint Inhibitor Therapy
  • Patients who have previously received an immune checkpoint inhibitor (eg, anti-PD-L1, anti-PD-1, anti-CTLA-4) prior to enrollment must have toxicities related to the checkpoint inhibitor resolved to ≤ Grade 1 or baseline (prior to the checkpoint inhibitor) to be eligible for enrollment. (see also Exclusion Criteria 10). Note that patients who experienced previous hypothyroidism toxicity on a checkpoint inhibitor are eligible to enter study regardless of CTCAE Grade resolution as long as the patient is well controlled on thyroid replacement hormone.

Exclusion Criteria

  • Patients with symptomatic central nervous system (CNS) metastases must have been treated, be asymptomatic, and not have any of the following at the time of enrollment:
  • Need for concurrent treatment for the CNS disease (eg, surgery, radiation, corticosteroids > 10 mg prednisone / day or equivalent);
  • Progression of CNS metastases on MRI or CT for at least 28 days after last day of prior therapy for the CNS metastases; and/or
  • Concurrent leptomeningeal disease or cord compression.
  • Patients with any history of known or suspected autoimmune disease with the specific exceptions of the following:
  • Vitiligo
  • Resolved childhood atopic dermatitis
  • Psoriasis (with exception of psoriatic arthritis) not requiring systemic treatment (within the past 2 years)
  • Patients with a history of Grave's disease that are now euthyroid clinically and by laboratory testing
  • History of prior allogeneic bone marrow, stem-cell or solid organ transplantation.
  • Treatment with any systemic anti-neoplastic therapy, or investigational therapy within the 2 weeks prior to the initiation of study drug administration. Patients may be on an investigational or other anti-neoplastic therapy during the screening phase of the study.
  • Treatment with radiation therapy within 2 weeks prior to the initiation of study drug administration.
  • Treatment with corticosteroids (>10 mg per day prednisone or equivalent) or other immune suppressive drugs within the 14 days prior to the initiation of study drug administration. Steroids for topical, ophthalmic, inhaled, or nasal administration are allowed. Physiological replacement with hydrocortisone up to a maximum dose of 40 mg per day is allowed.
  • History of clinically significant cardiovascular disease including, but not limited to:
  • Myocardial infarction or unstable angina within the 16 weeks prior to the initiation of study drug
  • Clinically significant cardiac arrhythmias
  • Uncontrolled hypertension: systolic blood pressure (BP) >180 mmHg, diastolic BP >100 mmHg
  • Deep vein thrombosis, pulmonary embolism, stroke, or transient ischemic attack within the 16 weeks prior to the initiation of study drug
  • QTcB prolongation > 480 msec
  • Congestive heart failure (New York Heart Association class III- IV)
  • Pericarditis/clinically significant pericardial effusion
  • Myocarditis
  • Clinically significant pulmonary compromise (eg, requirement for supplemental oxygen)
  • Clinically significant GI disorders including:
  • History of GI perforation within 1 year prior to study drug administration. Patients with a history of GI perforation that occurred more than 1 year ago can only be enrolled if the Investigator no longer considers the previously affected area to be at risk for perforation;
  • History of clinically significant GI bleeding within 3 months prior to the initiation of study drug;
  • History of acute pancreatitis within 3 months prior to the initiation of study drug; and/or
  • Diverticulitis that is clinically significant in the opinion of the Investigator based on the extent or severity of known disease and/or the occurrence of clinically significant disease flares within 4 weeks prior to the initiation of study drug administration.
  • Patients who experienced the following immune checkpoint inhibitor-related AEs are ineligible even if the AE resolved to ≤ Grade 1 or baseline:
  • ≥ Grade 3 ocular AE
  • Changes in liver function tests that met the criteria for Hy's Law (> 3 × ULN of either ALT/AST with concurrent >2 × ULN of total and direct bilirubin and without alternate etiology)
  • ≥ Grade 3 neurologic toxicity
  • ≥ Grade 3 colitis
  • ≥ Grade 3 renal toxicity
  • Evidence of active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 7 days prior to the initiation of study drug. Patients requiring any systemic antiviral, antifungal, or antibacterial therapy for active infection must have completed treatment no less than 1 week prior to the initiation of study drug.
  • Known positive testing for human immunodeficiency virus or history of acquired immune deficiency syndrome.
  • Known history of hepatitis B or hepatitis C infection or known positive test for hepatitis B surface antigen, hepatitis B core antigen, or hepatitis C polymerase chain reaction.
  • Second primary invasive malignancy that has not been in remission for greater than 2 years. Exceptions that do not require a 2-year remission include: non- melanoma skin cancer; cervical carcinoma in situ on biopsy; or squamous intraepithelial lesion on Pap smear; localized prostate cancer (Gleason score < 6); or resected melanoma in situ.
  • History of trauma or major surgery within 4 weeks prior to the initiation of study drug administration.
  • Any serious underlying medical or psychiatric condition that would impair the ability of the patient to receive or tolerate the planned treatment at the investigational site.
  • Known hypersensitivity to recombinant proteins, polysorbate 80 or any excipient contained in the drug formulation for CUE-101.
  • Vaccination with any live virus vaccine within 4 weeks prior to the initiation of study drug administration. Inactivated annual influenza vaccination is allowed.
  • Dementia or altered mental status that would preclude understanding and rendering of informed consent.
  • Active or history of alcohol or other substance abuse within 1 year prior to the initiation of study drug administration.
  • Any investigative site personnel directly affiliated with this study.
  • Prisoners or other individuals who are involuntarily detained.
  • Any issue that would contraindicate the patient's participation in the study or confound the results of the study.

Arizona

Tucson
Banner University Medical Center - Tucson
Status: ACTIVE

California

Palo Alto
Stanford Cancer Institute Palo Alto
Status: ACTIVE

Florida

Tampa
Moffitt Cancer Center
Status: ACTIVE

Georgia

Atlanta
Emory University Hospital / Winship Cancer Institute
Status: ACTIVE
Emory University Hospital Midtown
Status: ACTIVE

Massachusetts

Boston
Massachusetts General Hospital Cancer Center
Status: ACTIVE

Michigan

Ann Arbor
University of Michigan Comprehensive Cancer Center
Status: ACTIVE
Detroit
Wayne State University / Karmanos Cancer Institute
Status: ACTIVE

Missouri

Saint Louis
Siteman Cancer Center at Washington University
Status: ACTIVE

New York

New York
Memorial Sloan Kettering Cancer Center
Status: ACTIVE
Contact: Lara Ann Dunn
Phone: 646-888-4233

Tennessee

Nashville
Vanderbilt University / Ingram Cancer Center
Status: ACTIVE

Texas

Houston
M D Anderson Cancer Center
Status: ACTIVE

Washington

Seattle
Fred Hutch / University of Washington Cancer Consortium
Status: ACTIVE

CUE-101 is a novel fusion protein designed to activate and expand a population of tumor specific T cells to eradicate human papilloma virus (HPV)-driven malignancies. HPV causes multiple tumor types including cervical, head and neck squamous cell carcinoma (HNSCC) and anal cancers. Initial testing of CUE-101 will be conducted in HPV16+ HNSCC patients. The primary objectives of the Part A&B, first-in-human trial, are to assess the safety and tolerability of CUE-101 in subjects with recurrent/metastatic HNSCC in the second line setting and to determine the maximum tolerated dose or recommended Phase 2 dose based on markers of biological activity. Pharmacokinetics (PK), antitumor immune response, preliminary antitumor activity and the potential for immunogenicity will also be assessed. The goal of Part C&D is to characterize the safety, tolerability, and biological effects of CUE 101 in combination with pembrolizumab in patients with recurrent/metastatic HNSCC in the first line setting. This will be an open-label multicenter phase I trial conducted in the U.S. involving approximately 85 patients.

Trial Phase Phase I

Trial Type Treatment

Lead Organization
Cue BioPharma

  • Primary ID CUE-101-01
  • Secondary IDs NCI-2019-04589
  • Clinicaltrials.gov ID NCT03978689